Healthcare Equities

The companies that provide, support or coordinate medical goods and services. This sector spans a broad range of activities – including the development and manufacture of medical equipment, pharmaceuticals and other treatments. Activities range from research to manufacturing, administration, insurance and facilities management. Our Healthcare research includes healthcare services, healthcare information technology (IT), medical devices, biotechnology, biopharmaceuticals and specialty pharmaceuticals.

Roche (SIX: ROC) acquires 89bio for $3.5bn >

Finlay Mathers | Healthcare | Comment | 1 hour ago

Oryzon Genomics (BME: ORY) strengthens intellectual property profiles >

Arron Aatkar, PhD | Healthcare | Comment | 2 days ago

SEE ALL COMMENTARY >

Actinogen Medical (ACW)

Latest price

AUD0.03

— 0.00 (0.00)

As at 17/09/2025

Market capitalisation: AUD102m

View equity

Update

Healthcare

16.09.25

Actinogen Medical — An eventful period ahead for Xanamem

Update

Healthcare

07.07.25

Actinogen Medical — XanaMIA study enrols 100th patient

edison tv

Healthcare

10.04.25

NZD2.61

▾ 0.01 (0.38)

As at 17/09/2025

Market capitalisation: NZD273m

View equity

Flash

Healthcare

03.07.25

AFT Pharmaceuticals — Making progress on growth strategy

Update

Healthcare

03.06.25

AFT Pharmaceuticals — Setting the stage for sustained long-term growth

Update

Healthcare

29.11.24

SEK1.15

— 0.00 (0.35)

As at 17/09/2025

Market capitalisation: SEK120m

View equity

Non client QV

Healthcare

28.08.25

GBP0.50

▾ −2.50 (−4.76)

As at 17/09/2025

Market capitalisation: GBP54m

View equity

Argent Biopharma (RGT)

Latest price

AUD0.11

▾ 0.01 (4.76)

As at 17/09/2025

Market capitalisation: AUD9m

View equity

Update

Healthcare

14.10.24

Argent Biopharma — Valuation report

QuickView

Healthcare

05.09.24

Argent Biopharma — An innovative approach to drug development

Update

Healthcare

04.11.19

CHF46.05

▾ 0.15 (0.33)

As at 17/09/2025

Market capitalisation: CHF612m

View equity

edison tv

Healthcare

01.09.25

Basilea Pharmaceutica – executive interview

Update

Healthcare

01.09.25

Basilea Pharmaceutica — Gearing up for the next growth phase

Flash

Healthcare

15.08.25

USD1.96

▾ −0.06 (−2.97)

As at 17/09/2025

Market capitalisation: USD121m

View equity

Non client QV

Healthcare

29.01.25

SEK2.75

▾ −0.01 (−0.36)

As at 17/09/2025

Market capitalisation: SEK687m

View equity

Flash note

Healthcare

19.04.23

Cantargia — Encouraging data for nadunolimab in CANFOUR

Flash note

Healthcare

14.03.23

Cantargia — First patient treated in Phase II part of TRIFOUR

Update

Healthcare

27.02.23

SEK8.40

▾ −0.33 (−3.72)

As at 17/09/2025

Market capitalisation: SEK2,535m

View equity

edison tv

Healthcare

29.08.25

Cereno Scientific – executive interview

Update

Healthcare

28.08.25

Cereno Scientific — Momentum building ahead of Phase II

Update

Healthcare

17.07.25

SEK1.27

▾ −0.07 (−5.22)

As at 17/09/2025

Market capitalisation: SEK106m

View equity

thematic

Healthcare

04.01.24

Outlook for 2024: Life sciences – where has the conviction gone?

Update

Healthcare

02.06.23

Chosa Oncology — Making headway in precision oncology

Update

Healthcare

28.02.22

GBP0.12

— 0.00 (0.00)

As at 17/09/2025

Market capitalisation: GBP51m

View equity

Flash

Healthcare

22.07.25

Creo Medical — H1 momentum underpins FY25 confidence

Flash

Healthcare

11.06.25

Creo Medical — SpydrBlade Flex set to enter the US market

edison tv

Healthcare

27.05.25

SEK5.19

▾ −0.22 (−4.07)

As at 17/09/2025

Market capitalisation: SEK263m

View equity

Non client QV

Healthcare

26.02.25

EUR1.70

▾ −0.04 (−2.02)

As at 17/09/2025

Market capitalisation: EUR42m

View equity

Spotlight — update

Healthcare

22.08.25

Herantis Pharma — H125 results reflect Phase Ib progress

Spotlight — flash

Healthcare

15.08.25

Herantis Pharma — Last patient visit completed for Phase Ib

Spotlight — initiation

Healthcare

22.05.25

EUR6.10

▾ −0.10 (−1.61)

As at 17/09/2025

Market capitalisation: EUR174m

View equity

Immix Biopharma (IMMX)

Latest price

USD1.96

▾ −0.04 (−2.00)

As at 17/09/2025

Market capitalisation: USD58m

View equity

Flash

Healthcare

12.09.25

Immix Biopharma — $9m private placement to support operations

Update

Healthcare

19.08.25

Immix Biopharma — Fleshing out the CAR-T strategy

Flash

Healthcare

06.06.25

SEK2.99

▾ 0.12 (4.18)

As at 17/09/2025

Market capitalisation: SEK261m

View equity

Flash

Healthcare

27.03.25

IRLAB Therapeutics — Next steps laid out for IRL757

Update

Healthcare

06.03.25

IRLAB Therapeutics — Pirepemat stumbles in Phase IIb study

Flash

Healthcare

20.02.25

IRLAB Therapeutics — EMA alignment on mesdopetam Phase III plans

See more
content on

IRLAB Therapeutics

Equities

Equities by Sector

Sectors

Thematics

Latest

Edison explains: PISCES decoded – what is it and why was it created?

Edison explains: Climate accountability – hidden emissions or financial reality?

MediaWatch – A two-tier story

Audiovisual

Latest

Earnz – executive interview

Global Fashion Group – executive interview

OSE Immunotherapeutics – executive interview

About Edison

About Edison

Careers

Healthcare Equities

Actinogen Medical (ACW)

AUD0.03

Actinogen Medical — An eventful period ahead for Xanamem

Actinogen Medical — XanaMIA study enrols 100th patient

Actinogen Medical – equity proposition

See morecontent on

AFT Pharmaceuticals (AFT)

NZD2.61

AFT Pharmaceuticals — Making progress on growth strategy

AFT Pharmaceuticals — Setting the stage for sustained long-term growth

AFT Pharmaceuticals — Softer H1 on one-offs; recovery expected in H2

See morecontent on

Alzinova (ALZ)

SEK1.15

Alzinova — Innovative new approach to Alzheimer's

See morecontent on

AOTI (AOTI)

GBP0.50

Argent Biopharma (RGT)

AUD0.11

Argent Biopharma — Valuation report

Argent Biopharma — An innovative approach to drug development

MGC Pharmaceuticals — Rapid prescription growth in Australia and the UK

See morecontent on

Basilea Pharmaceutica (BSLN)

CHF46.05

Basilea Pharmaceutica – executive interview

Basilea Pharmaceutica — Gearing up for the next growth phase

Basilea Pharmaceutica — New acquisition bolsters antibacterial franchise

See morecontent on

Biomea Fusion (BMEA)

USD1.96

Biomea Fusion — An innovative approach to diabetes and obesity

See morecontent on

Cantargia (CANTA)

SEK2.75

Cantargia — Encouraging data for nadunolimab in CANFOUR

Cantargia — First patient treated in Phase II part of TRIFOUR

Cantargia — Next phase of clinical development in sight

See morecontent on

Cereno Scientific (CRNO-B)

SEK8.40

Cereno Scientific – executive interview

Cereno Scientific — Momentum building ahead of Phase II

Cereno Scientific — Phase II calling for CS014 after Phase I success

See morecontent on

Chosa (CHOSA)

SEK1.27

Outlook for 2024: Life sciences – where has the conviction gone?

Chosa Oncology — Making headway in precision oncology

RhoVac — On the home straight

See morecontent on

Creo Medical (CREO)

GBP0.12

Creo Medical — H1 momentum underpins FY25 confidence

Creo Medical — SpydrBlade Flex set to enter the US market

Creo Medical – executive interview

See morecontent on

Elicera Therapeutics (ELIC)

SEK5.19

Elicera Therapeutics — Positioned to deliver in cell and gene therapies

See morecontent on

Herantis Pharma (HRTIS)

See more
content on

See more
content on

See more
content on

See more
content on

See more
content on

See more
content on

See more
content on

See more
content on

See more
content on

See more
content on

See more
content on

See more
content on

See more
content on

See more
content on